Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Familial Testicular Germ Cell Tumors

Identifying risks for family males

Publish date:: September 1, 2015

Despite relatively low numbers of individuals per family affected by testicular germ cell tumors (TGCTs), members of families with multiple people affected and members of families with people affected by sporadic-bilateral TGCT are high-risk groups for incident testicular cancer. This according to a study of 1,260 men with TGCT from 140 families. Researchers found:

• 8 incident TGCTs occurred during follow-up, for an excess absolute risk of 7.2 per 10,000.

• The incidence rate of TGCT is greater among bloodline male relatives from families that have experienced multiple cases of testicular cancer than the rate expected in the general population.

• This pattern is characteristic of adult-onset Mendelian cancer susceptibility disorders.

• 2 of the incident TGCTs occurred in relatives of patients with sporadic-bilateral disease.

Citation: Pathak A, Adams CD, Loud JT, Nichols K, Stewart DR, Greene MH. Prospectively-identified incident testicular cancer risk in a familial testicular cancer cohort. [Published online ahead of print August 11, 2015]. Cancer Epidemiol Biomarkers Prev. doi: 10.1158/1055-9965.EPI-14-1240.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,